DaltonTx Secures £4 Million to Advance AI Drug Discovery Platform

DaltonTx, a UK-based technology company, has announced its emergence from stealth mode alongside the completion of a £4 million seed financing round. This funding aims to support the development of adaptive, AI-enabled discovery platforms designed to transform the economics and timelines of pharmaceutical R&D, announced in a press release.

The platform developed by DaltonTx is disease- and technology-agnostic, integrating directly into the workflows of pharmaceutical companies, biotech firms, and contract research organizations (CROs). This integration allows these entities to access AI-enabled discovery capabilities without the need for extensive in-house development. The platform not only focuses on predictive modeling but also encompasses the entire discovery process, from raw data and model training to molecular design and synthesis.

DaltonTx was co-founded by a team of experts with extensive experience in drug discovery, machine learning, and software engineering, including Dr. Garry Pairaudeau, Adrian Rossall, Dr. Anthony Bradley, and Professor Charlotte Deane MBE. The company is strategically positioned in London's tech and life sciences hub at King's Cross, aiming to redefine how technology can transform drug discovery.